CJC-1295 No DAC Pre-Cycle vs Post-Cycle Research: What Wholesale Buyers Should Know

In research literature, "pre-cycle" and "post-cycle" do not describe two different compounds, two different grades, or two different protocols. They describe when data is collected relative to an administration window inside a study design — pre-cycle work establishes baseline measurements before a compound is introduced, and post-cycle work measures what changed after that window closed. The compound itself, a modified GRF(1-29) fragment without the drug affinity complex, is identical in both cases.

That matters for a wholesale buyer in a specific and narrow way: the distinction changes nothing about what you stock, and everything about the documentation your customers will ask you to produce. Baseline-and-follow-up designs live or die on whether the material used at the start of a study is demonstrably the same material used at the end. That is a supply-chain question, not a protocol question — and it is the one you can actually control.

Pre-cycle and post-cycle are study-design terms, not product variants

Any controlled research design has a before and an after. In preclinical work involving growth hormone secretagogues and releasing-hormone analogues, investigators typically take baseline biochemical and physiological measurements, introduce the compound across a defined window, then re-measure once that window ends. The "pre" phase generates the control data. The "post" phase generates the comparison data. Research suggests the interpretive value of this class of compound depends heavily on how tightly those two measurement points are matched — same assay, same conditions, same lot of test material.

Where buyers go wrong is reading the phrases as SKUs. There is no pre-cycle formulation and no post-cycle formulation. If a supplier ever implies otherwise — that one vial is for "starting" and another for "finishing" — that is a marketing construct, not chemistry, and it is a reason to walk.

CJC-1295 No DAC is a short-acting analogue precisely because the DAC moiety, which extends circulating half-life, is absent. Studies indicate that this shorter profile is what makes the compound interesting to researchers designing pulsatile rather than sustained-exposure models. That single structural fact — present or absent DAC — is the only meaningful product distinction in this category, and it belongs on your spec sheet. "Cycle" language does not.

Side-by-side: how the two framings differ

Read across the last two rows and the buying implication is obvious. Pre-phase questions are answered by a certificate of analysis you can pull before you order. Post-phase questions are answered by whether your supplier can still show you that certificate six months later — and whether the next lot they ship you is characterised to the same standard.

Where the "cycle" vocabulary came from, and why it doesn't belong on a product page

The pre/post-cycle phrasing did not originate in peer-reviewed research. It migrated from consumer and forum culture, where "cycle" carries assumptions about duration, sequencing, and personal use. Search volume follows that vocabulary, which is why the phrase shows up in keyword tools — but a reseller who adopts it in catalog copy inherits every assumption attached to it.

Real Peptides supplies research-use-only compounds and does not publish dosing, titration, sequencing, or preparation guidance for any item in the catalog, including CJC-1295 No DAC. That is not evasiveness; it is the line that keeps a research-supply business a research-supply business. Compounds in this category are not FDA-approved drugs and are not intended for human consumption.

The furthest any responsible supplier-side education goes is the concentration framework: a stated mass of lyophilised peptide per vial, and the arithmetic that mass per volume of solvent yields a concentration expressed in milligrams per millilitre. That is a units relationship any researcher already knows how to apply. Anything past it — volumes to withdraw, sequencing across days, device references — is protocol guidance, and it does not appear in Real Peptides materials in any form, converted or otherwise.

For resellers, the practical upside is that neutral, spec-led copy ages better. Product pages built on molecular weight, sequence, purity method, and lot number don't need rewriting when platform policies tighten.

What actually varies between lots, and what your customers are really asking

When a research customer asks about pre- versus post-cycle material, the question underneath is almost always about consistency. They want to know that the vial they characterise at baseline and the vial they use at follow-up are the same substance at the same strength. Three things determine that answer.

Identity. Confirmation that the sequence in the vial is the sequence on the label. Mass spectrometry is the standard method for this, and its absence from a COA is conspicuous.

Purity. Reported as a percentage by high-performance liquid chromatography, with the chromatogram attached rather than summarised. Purity and peptide content are different figures; buyers who conflate them end up surprised. Ask which one a supplier is quoting.

Batch-level contamination markers. Testing programs in this space generally look beyond identity and purity to markers that indicate how the material was made and handled. The specific panel varies by supplier, so the useful question is not "do you test?" but "what does your panel cover, per lot, and can I see the report for the lot you would ship me?"

A supplier who answers those three with documents rather than adjectives is a supplier whose material can anchor a baseline-and-follow-up design. One who answers with reassurance cannot.

Supplier due diligence: the questions that separate wholesale programs

Wholesale programs in research peptides differ more in transparency than in catalog. A short list of questions surfaces most of it.

Is pricing published or quote-only? Quote-only isn't automatically a problem, but opaque pricing makes it impossible to model category economics before you commit. Margins in this category vary widely with volume, compound, and how you position the line — anyone quoting you a specific margin figure is guessing on your behalf.

Are COAs free, public, and lot-matched? The practice worth avoiding is COAs sold as an add-on, or a single generic certificate reused across lots. You want to verify results yourself, for the specific lot, before money moves.

Is the testing verifiable? "Third-party tested" means little without a named lab, a date, and a document. Unverifiable testing claims are the most common weak point in this market.

Where does fulfillment originate, and how consistent is reorder supply? A compound you cannot restock on a predictable cadence is a compound you cannot build a catalog line around.

What are the minimum order mechanics? Ask how tiers are structured, whether minimums apply per compound or per order, and whether pricing steps down by volume. Program minimums differ enormously across suppliers, so compare the actual terms you're quoted rather than any published rule of thumb.

Compliance questions to route through your own counsel

This section is informational and is not legal advice. Whether your business may stock, relabel, or resell research-use-only compounds depends on your entity type, your licensure, and how your jurisdiction treats research-supply activity — and those answers are not uniform. Rather than assuming a position, bring specific questions to your attorney and your state board: How is research-use-only material classified for a business like mine? Does my license type change what I may hold or transfer? What labeling and record-keeping obligations attach to reselling? What does my insurer require to be disclosed? What restrictions apply to how I advertise this category?

General frameworks exist, but state-level specifics vary and change, so verify current requirements directly with your board rather than relying on a supplier's summary. Any wholesale partner who hands you a confident legal conclusion instead of pointing you to counsel is telling you something about their diligence, not yours.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built around documentation the buyer can check independently rather than take on faith.

Every compound is produced to 99%+ HPLC purity. Each batch goes through a seven-panel testing program, and the resulting certificates of analysis are published and publicly verifiable — the reader can look up lab results for a lot directly, at no cost and without asking a rep. That is the specific practice that makes baseline-and-follow-up research designs workable on the supply side: the document exists before you buy and remains available after.

Fulfillment originates in the United States, with a stated delivery window of five to seven days. The wholesale application is a three-step process rather than an extended negotiation, and pricing tiers are explained rather than dangled.

None of this describes what any compound does for a customer. It describes what a supplier owes a business buyer: verifiable identity, verifiable purity, lot-level records, and a reorder path that doesn't break.

If your business is qualified — a clinic, med spa, wellness center, telehealth operator, or reseller building a catalog on characterised material rather than marketing copy — the Wholesale Partner Program application at realpeptides.co is the next step, and the published COAs are worth reviewing before you start it.

Buyers comparing this category often look at CJC-1295 No DAC 10mg alongside related secretagogue research compounds such as Ipamorelin 10mg and Tesamorelin 10mg, and the broader Growth Factor & Tissue Signaling Research collection shows how the same purity and batch-testing standard applies across the line.